PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support ...

Patients who took the higher dose of Innovent’s mazdutide for 48 weeks lost nearly 15% of their body weight in a study of more than 610 Chinese people who were either overweight or obese ...

Lilly has also partnered with Chinese drug developer Innovent Biologics on an anti-obesity drug called mazdutide. Innovent’s market application for mazdutide was accepted for review by Chinese ...

Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and Eli Lilly.